CD96 Binding Proteins for Blocking CD155 Immune Inhibition

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

There is a need for improved antigen binding proteins that target CD96 for the treatment of diseases, as little is known about its function and existing technologies have not effectively addressed its role in immune regulation.

Innovation Solution

Development of CD96 binding proteins, nucleic acid constructs, expression vectors, and recombinant host cells to produce CD96 binding proteins, which can be used in pharmaceutical compositions for therapeutic applications.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If CD96 binding proteins are developed to block CD155-CD96 interaction, then immune inhibition is inhibited and therapeutic benefit is improved, but knowledge about CD96 function remains limited and mechanism understanding is insufficient

Engineering Contradiction:

Improvetherapeutic efficacyVSAvoidmechanism understanding

Core Design Contradiction:

ReliabilityVSLoss of information

Solution Approach 1:

The patent segments the CD96 receptor into its ligand-binding domain (extracellular domain) and develops binding proteins that specifically target this domain. This segmentation allows blocking of the CD155-CD96 interaction without requiring complete understanding of the entire CD96 signaling mechanism, enabling therapeutic development despite limited functional knowledge of CD96

Inventive Principle:

Principle #1Segmentation

Solution Approach 2:

The patent introduces CD96 binding proteins as intermediary molecules that mediate the blocking of CD155 binding to CD96. These binding proteins serve as the active therapeutic agents that interfere with the natural ligand-receptor interaction, providing therapeutic benefit while the actual mechanism of CD96 signaling can be studied separately through research

Inventive Principle:

Principle #24Intermediary (Mediator)

2Adaptability or versatility

If CD96 binding proteins are used to treat diseases, then therapeutic applications are expanded, but the complexity of developing and characterizing new antigen binding proteins increases

Engineering Contradiction:

Improvetherapeutic applicationsVSAvoiddevelopment complexity

Core Design Contradiction:

Adaptability or versatilityVSDevice complexity

Solution Approach 1:

The patent develops CD96 binding proteins with universal application potential across multiple disease states involving CD96-mediated immune inhibition. The binding proteins are designed to target the conserved CD96 receptor structure, enabling broad therapeutic applicability against different cancers and immune-related diseases while using a standardized development platform for antigen binding proteins

Inventive Principle:

Principle #6Universality (Multi-functionality)

Solution Approach 2:

The patent employs parameter changes in the development process, including optimizing binding affinity, specificity, and stability parameters of the CD96 binding proteins. By systematically adjusting these parameters during development and characterization, the patent manages complexity through structured optimization rather than unguided experimentation

Inventive Principle:

Principle #35Parameter changes

Data Source

PatentUS12528864B2Antigen binding proteins

Publication Date: 2026.01.20 GLAXOSMITHKLINE INTPROP DEV LTD

AI summary

The present disclosure relates to compositions for treating CD96 mediated diseases, and related methods.